Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MAYER J HASBANI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Clinical Neurophysiology

NPI
1780632968
CMS profile
307932
Location
NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$80,886.83

501 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Otsuka America Pharmaceutical, Inc. $27,581.20 38
Eisai Inc. $16,183.64 26
Teva Pharmaceuticals USA, Inc. $12,027.79 60
ABBVIE INC. $6,983.17 63
GENZYME CORPORATION $3,862.28 10
SANOFI-AVENTIS U.S. LLC $3,601.66 3
EMD Serono, Inc. $2,696.22 31
Novartis Pharmaceuticals Corporation $800.37 26
Biogen, Inc. $572.02 19
SK Life Science, Inc. $540.79 21
Genentech USA, Inc. $502.27 13
TG Therapeutics, Inc. $393.58 12
Horizon Therapeutics plc $376.09 11
ARGENX US, INC. $338.96 6
Mallinckrodt Hospital Products Inc. $284.57 9
Kyowa Kirin, Inc. $280.36 18
Lundbeck LLC $235.10 7
Neurocrine Biosciences, Inc. $230.68 9
Sumitomo Pharma America, Inc. $219.70 7
Amneal Pharmaceuticals LLC $216.33 16
UCB, Inc. $214.34 6
Neurelis, Inc. $197.36 4
Alnylam Pharmaceuticals Inc. $196.76 4
MDD US Operations, LLC $188.79 4
Amgen Inc. $183.58 10
Amylyx Pharmaceuticals, Inc. $181.65 4
ANI Pharmaceuticals, Inc. $175.02 3
Lilly USA, LLC $172.89 8
Alexion Pharmaceuticals, Inc. $167.70 4
PFIZER INC. $167.70 8
Axsome Therapeutics, Inc. $145.07 3
Grifols USA, LLC $143.53 6
Medtronic, Inc. $93.64 1
Catalyst Pharmaceuticals, Inc. $92.99 4
Mylan Specialty L.P. $86.47 1
Avadel CNS Pharmaceuticals, LLC $79.24 4
Takeda Pharmaceuticals U.S.A., Inc. $60.16 3
Octapharma USA, Inc. $49.55 2
Ipsen Biopharmaceuticals, Inc $41.42 2
Celgene Corporation $32.62 2
CSL Behring $30.95 1
Baxter Healthcare $28.81 1
Avion Pharmaceuticals $28.42 1
Almatica Pharma LLC $24.16 1
AstraZeneca Pharmaceuticals LP $22.21 1
Supernus Pharmaceuticals, Inc. $22.06 1
IDORSIA PHARMACEUTICALS US INC $21.03 1
Bayer Healthcare Pharmaceuticals Inc. $20.56 1
Alkermes, Inc. $20.46 1
Acorda Therapeutics, Inc $18.97 1
Azurity Pharmaceuticals, Inc. $18.37 1
Abbott Laboratories $16.84 1
Scilex Pharmaceuticals Inc. $16.73 1

Page 5 of 11; records 201–250 of 501 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MAYER J HASBANI

NPI 1780632968 · CMS profile ID 307932

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Clinical Neurophysiology

NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 11; records 201–250 of 501 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780632968?year=2023&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MAYER J HASBANI, NPI 1780632968, CMS profile ID 307932. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 11; records 201–250 of 501 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780632968?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MAYER J HASBANI, NPI 1780632968, CMS profile ID 307932. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 11; records 201–250 of 501 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780632968?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MAYER J HASBANI, NPI 1780632968, CMS profile ID 307932, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 11; records 201–250 of 501 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1780632968?year=2023&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

501 matching records · $80,886.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 501 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 501.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Otsuka America Pharmaceutical, Inc. $52.8607/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014392263 CMS
Otsuka America Pharmaceutical, Inc. $343.7407/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014392269 CMS
Otsuka America Pharmaceutical, Inc. $65.1407/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014392277 CMS
Otsuka America Pharmaceutical, Inc. $57.4407/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014392285 CMS
Teva Pharmaceuticals USA, Inc. $119.1307/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056719775 CMS
Teva Pharmaceuticals USA, Inc. $2,100.0007/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056719927 CMS
Otsuka America Pharmaceutical, Inc. $2,888.0007/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014392241 CMS
Otsuka America Pharmaceutical, Inc. $1,976.0007/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014392249 CMS
Otsuka America Pharmaceutical, Inc. $125.0007/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014392257 CMS
Teva Pharmaceuticals USA, Inc. $10.7607/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056719899 CMS
ABBVIE INC. $24.6407/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997447201 CMS
Teva Pharmaceuticals USA, Inc. $19.3307/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056719925 CMS
Eisai Inc. $235.9007/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023372873 CMS
EMD Serono, Inc. $23.3607/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032549986 CMS
SK Life Science, Inc. $16.2907/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054646699 CMS
ABBVIE INC. $12.5407/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997447199 CMS
Otsuka America Pharmaceutical, Inc. $908.4207/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014392225 CMS
Otsuka America Pharmaceutical, Inc. $79.7807/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014392233 CMS
Otsuka America Pharmaceutical, Inc. $125.0007/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014392217 CMS
Teva Pharmaceuticals USA, Inc. $16.1307/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056719897 CMS
ABBVIE INC. $15.7907/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997447197 CMS
Horizon Therapeutics plc $17.3407/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987016493 CMS
Amgen Inc. $23.4907/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020021293 CMS
Alexion Pharmaceuticals, Inc. $18.6407/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017039129 CMS
Alexion Pharmaceuticals, Inc. $3.2207/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017057197 CMS
ABBVIE INC. $11.3007/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997447195 CMS
Novartis Pharmaceuticals Corporation $23.5307/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992131395 CMS
TG Therapeutics, Inc. $15.8407/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051481457 CMS
EMD Serono, Inc. $3.3207/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032548955 CMS
Eisai Inc. $98.2407/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023322457 CMS
Eisai Inc. $3,510.0007/12/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023322503 CMS
Neurocrine Biosciences, Inc. $12.9507/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052039469 CMS
Grifols USA, LLC $19.0807/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011814511 CMS
Teva Pharmaceuticals USA, Inc. $6.5307/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056719903 CMS
Teva Pharmaceuticals USA, Inc. $10.3807/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056719769 CMS
ABBVIE INC. $17.9607/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997447193 CMS
ARGENX US, INC. $29.3907/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060404917 CMS
EMD Serono, Inc. $1,800.0007/07/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052753017 CMS
Celgene Corporation $18.3606/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014947199 CMS
Avion Pharmaceuticals $28.4206/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032978549 CMS
Catalyst Pharmaceuticals, Inc. $20.8006/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048231743 CMS
Sumitomo Pharma America, Inc. $7.3006/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030914421 CMS
EMD Serono, Inc. $110.9606/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032419125 CMS
Amneal Pharmaceuticals LLC $20.7606/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053498573 CMS
Amylyx Pharmaceuticals, Inc. $21.1406/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057676235 CMS
Eisai Inc. $300.7106/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023322495 CMS
Eisai Inc. $50.0006/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023322497 CMS
Eisai Inc. $50.0006/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023322499 CMS
Eisai Inc. $12.5006/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023322501 CMS
Baxter Healthcare $28.8106/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996988344 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $71,009.76 479
PY2020 $49,267.75 387
PY2021 $83,560.62 503
PY2022 $107,504.48 494
PY2023 $80,886.83 501
PY2024 $85,002.03 514
PY2025 $105,167.91 433

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $490,883.03 48
PY2024 Principal investigator $88,369.86 24
PY2023 Principal investigator $86,758.00 28
PY2022 Principal investigator $35,146.00 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $175.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293365
Principal investigator 1 Ipsen Innovation $4,900.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293367
Principal investigator 1 Ipsen Innovation $4,970.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293369
Principal investigator 1 Ipsen Innovation $1,050.00 11/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293371
Principal investigator 1 Ipsen Innovation $90.00 11/13/2025 Non-covered Recipient Entity
Hasbani Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287342
Principal investigator 1 Ipsen Pharma SAS $4,000.00 10/31/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307149
Principal investigator 1 Ipsen Innovation $90.00 10/29/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287340
Principal investigator 1 Ipsen Innovation $175.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293333
Principal investigator 1 Ipsen Innovation $175.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293335
Principal investigator 1 Ipsen Innovation $175.00 10/27/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293337
Principal investigator 1 Merz Pharmaceuticals, LLC $15,000.00 09/26/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647358
Principal investigator 1 Merz Pharmaceuticals, LLC $15,000.00 09/26/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647370
Principal investigator 1 Merz Pharmaceuticals, LLC $2,500.00 09/26/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647378
Principal investigator 1 Merz Pharmaceuticals, LLC $2,500.00 09/26/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647380
Principal investigator 1 Ipsen Innovation $10,000.00 09/17/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293233
Principal investigator 1 Ipsen Innovation $2,000.00 09/17/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293235
Principal investigator 1 Ipsen Innovation $1,800.00 09/17/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293237
Principal investigator 1 Ipsen Innovation $150.00 09/09/2025 Non-covered Recipient Entity
Hasbani Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287334
Principal investigator 1 Ipsen Innovation $90.00 09/09/2025 Non-covered Recipient Entity
Hasbani Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287336
Principal investigator 1 Ipsen Innovation $150.00 09/09/2025 Non-covered Recipient Entity
Hasbani Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287338
Principal investigator 1 Ipsen Pharma SAS $2,500.00 08/29/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307119
Principal investigator 1 Ipsen Pharma SAS $2,000.00 08/29/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307125
Principal investigator 1 Ipsen Pharma SAS $2,500.00 08/29/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307127
Principal investigator 1 Ipsen Pharma SAS $2,000.00 08/29/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307129
Principal investigator 1 Ipsen Pharma SAS $2,500.00 08/29/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307131
Principal investigator 1 Ipsen Pharma SAS $2,000.00 08/29/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307133
Principal investigator 1 Ipsen Innovation $2,000.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293217
Principal investigator 1 Ipsen Innovation $175.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293219
Principal investigator 1 Ipsen Innovation $175.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293221
Principal investigator 1 Ipsen Innovation $175.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293223
Principal investigator 1 Ipsen Innovation $175.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293225
Principal investigator 1 Ipsen Innovation $10,000.00 08/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293227
Principal investigator 1 Ipsen Innovation $1,800.00 08/20/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184293215
Principal investigator 1 Ipsen Innovation $90.00 08/18/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287322
Principal investigator 1 Ipsen Innovation $150.00 08/18/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287324
Principal investigator 1 Ipsen Innovation $150.00 08/18/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287326
Principal investigator 1 Ipsen Innovation $180.00 08/08/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287328
Principal investigator 1 Ipsen Innovation $300.00 08/08/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287330
Principal investigator 1 Ipsen Innovation $300.00 08/08/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287332
Principal investigator 1 Ipsen Pharma SAS $4,676.00 08/08/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307121
Principal investigator 1 Ipsen Pharma SAS $4,676.00 08/08/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307123
Principal investigator 1 Ipsen Innovation $300.00 07/31/2025 Non-covered Recipient Entity
Hasbani Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287316
Principal investigator 1 Ipsen Innovation $180.00 07/31/2025 Non-covered Recipient Entity
Hasbani Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287318
Principal investigator 1 Ipsen Innovation $300.00 07/31/2025 Non-covered Recipient Entity
Hasbani Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287320
Principal investigator 1 Ipsen Innovation $175.00 07/28/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184293101
Principal investigator 1 Ipsen Innovation $482.00 05/15/2025 Non-covered Recipient Entity
Hasbani Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287314
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,468.03 01/27/2025 Non-covered Recipient Entity
Hasbani Neurology
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235997021
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $372,466.00 01/16/2025 Non-covered Recipient Entity
Hasbani Neurology
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235997019